This is a multicenter observational study with a retrospective and a prospective cohort investigating clinically and biologically the APL-like subset as a potential predictor of coagulopathy and susceptibility to early vascular events.
Patients with de novo AML, untreated, newly diagnosed, according to WHO/ICC 2022 criteria from January 2015 onwards.
Presence of NPM1 mutation.
Availability of immunophenotypic characterization at diagnosis
Age >= 18 years
No specific exclusion criteria are provided once eligibility criteria are met.
The study cohort will include NPM1mut AML patients with an immunophenotypic characterization at diagnosis that allows the classification into APL-like and non-APL-like AML.
Cohort
Prospective
observation of incidence of early vascular events
Other interventionobservation of difference incidence of early vascular events in the two cohorts
Incidence of early vascular events
Evaluation of the incidence of early vascular events (haemorrhagic and/or thrombotic) in the APL-like and non-APL-like subsets.
Click on the lead sponsor to view all of their trials.
